Distinguishing exercise intolerance in early-stage pulmonary hypertension with invasive exercise hemodynamics: Rest V
ETCO2
VE/VCO2
cardiopulmonary exercise test
invasive exercise hemodynamics
pulmonary hypertension
pulmonary vascular disease
Journal
Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
revised:
29
03
2022
received:
21
01
2022
accepted:
05
04
2022
pubmed:
15
4
2022
medline:
20
7
2022
entrez:
14
4
2022
Statut:
ppublish
Résumé
Among subjects with exercise intolerance and suspected early-stage pulmonary hypertension (PH), early identification of pulmonary vascular disease (PVD) with noninvasive methods is essential for prompt PH management. Rest gas exchange parameters (minute ventilation to carbon dioxide production ratio: V We conducted a retrospective review of 55 subjects with early-stage PH (per echocardiogram), undergoing invasive exercise hemodynamics with cardiopulmonary exercise test to distinguish exercise intolerance mechanisms. Based on the rest and exercise hemodynamics, three distinct phenotypes were defined: (1) PVD, (2) pulmonary venous hypertension, and (3) noncardiac dyspnea (no rest or exercise PH). For all tests, *p < .05 was considered statistically significant. The mean age was 63.3 ± 13.4 years (53% female). In the overall cohort, higher rest V In a broad cohort of subjects with suspected early-stage PH, referred for invasive exercise testing to distinguish mechanisms of exercise intolerance, rest gas exchange parameters (V
Sections du résumé
BACKGROUND
BACKGROUND
Among subjects with exercise intolerance and suspected early-stage pulmonary hypertension (PH), early identification of pulmonary vascular disease (PVD) with noninvasive methods is essential for prompt PH management.
HYPOTHESIS
OBJECTIVE
Rest gas exchange parameters (minute ventilation to carbon dioxide production ratio: V
METHODS
METHODS
We conducted a retrospective review of 55 subjects with early-stage PH (per echocardiogram), undergoing invasive exercise hemodynamics with cardiopulmonary exercise test to distinguish exercise intolerance mechanisms. Based on the rest and exercise hemodynamics, three distinct phenotypes were defined: (1) PVD, (2) pulmonary venous hypertension, and (3) noncardiac dyspnea (no rest or exercise PH). For all tests, *p < .05 was considered statistically significant.
RESULTS
RESULTS
The mean age was 63.3 ± 13.4 years (53% female). In the overall cohort, higher rest V
CONCLUSIONS
CONCLUSIONS
In a broad cohort of subjects with suspected early-stage PH, referred for invasive exercise testing to distinguish mechanisms of exercise intolerance, rest gas exchange parameters (V
Identifiants
pubmed: 35419844
doi: 10.1002/clc.23831
pmc: PMC9286332
doi:
Substances chimiques
Carbon Dioxide
142M471B3J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
742-751Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL147590
Pays : United States
Organisme : University of Wisconsin-Madison Department of Medicine Pilot Grant
ID : 233-AAH9756
Informations de copyright
© 2022 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.
Références
Pulm Circ. 2015 Dec;5(4):610-8
pubmed: 26697168
J Heart Lung Transplant. 2017 Jul;36(7):754-762
pubmed: 28131663
JACC Case Rep. 2021 Apr 14;3(7):1038-1043
pubmed: 34317680
Circulation. 2008 Nov 18;118(21):2183-9
pubmed: 18981305
JACC Heart Fail. 2016 Aug;4(8):607-16
pubmed: 27289406
Eur Respir J. 2009 Oct;34(4):888-94
pubmed: 19324955
Pulm Circ. 2015 Jun;5(2):398-406
pubmed: 26064467
Pulm Circ. 2020 Sep 17;10(3):2045894020950225
pubmed: 32994924
Int J Cardiol. 2011 Mar 3;147(2):189-90
pubmed: 21106265
J Am Coll Cardiol. 2000 Aug;36(2):547-56
pubmed: 10933371
Respiration. 2008;76(2):160-7
pubmed: 17960052
Circ Heart Fail. 2011 May;4(3):257-65
pubmed: 21411741
Am J Med. 2017 Nov;130(11):1272-1279
pubmed: 28552430
J Card Fail. 2017 Nov;23(11):777-782
pubmed: 28736291
Eur Respir J. 2017 Nov 22;50(5):
pubmed: 29167297
Circ Heart Fail. 2017 Sep;10(9):
pubmed: 28912263
Circ Heart Fail. 2015 Jan;8(1):41-8
pubmed: 25342738
Respir Med. 2009 Feb;103(2):317-24
pubmed: 18804360
Arthritis Rheum. 2010 Dec;62(12):3741-50
pubmed: 20722025
Clin Cardiol. 2022 Jul;45(7):742-751
pubmed: 35419844
Pulm Circ. 2022 Jan 12;12(1):e12029
pubmed: 35506089
J Card Fail. 2015 Aug;21(8):647-55
pubmed: 25887446
J Cardiovasc Surg (Torino). 2018 Jun;59(3):428-437
pubmed: 28870062
Chest. 2005 May;127(5):1637-46
pubmed: 15888840
Circulation. 2013 Sep 24;128(13):1470-9
pubmed: 24060943
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545968
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Expert Rev Respir Med. 2011 Apr;5(2):281-93
pubmed: 21510737
Chest. 2020 Nov;158(5):2119-2129
pubmed: 32473950
Circ Cardiovasc Imaging. 2012 Nov;5(6):765-75
pubmed: 22914595
Pulm Circ. 2019 Jan-Mar;9(1):2045894018803873
pubmed: 30204062
Eur Heart J. 2014 Nov 21;35(44):3103-12
pubmed: 25161181
Eur Respir J. 2015 Sep;46(3):728-37
pubmed: 26022955
Circ Heart Fail. 2018 May;11(5):e004750
pubmed: 29695381
Eur J Appl Physiol. 2000 Sep;83(1):63-70
pubmed: 11072775
J Am Coll Cardiol. 2020 Jan 7;75(1):17-26
pubmed: 31918830
Eur J Prev Cardiol. 2014 Jul;21(7):847-54
pubmed: 23382540
Echocardiography. 2017 Nov;34(11):1584-1592
pubmed: 28942616
Clin Med Insights Circ Respir Pulm Med. 2013 Sep 22;7:53-60
pubmed: 24093002
Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):487-92
pubmed: 10673190
Circ Heart Fail. 2014 Mar 1;7(2):367-77
pubmed: 24643889
J Cardiovasc Transl Res. 2022 Feb;15(1):116-130
pubmed: 34110608
BMJ. 2018 Mar 14;360:j5492
pubmed: 29540357